Last Updated: May 12, 2026

Profile for Australia Patent: 2025204582


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Australia Patent: 2025204582

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
11,192,895 Dec 12, 2033 Takeda Pharms Usa ICLUSIG ponatinib hydrochloride
11,192,897 Dec 12, 2033 Takeda Pharms Usa ICLUSIG ponatinib hydrochloride
11,384,086 Dec 12, 2033 Takeda Pharms Usa ICLUSIG ponatinib hydrochloride
9,493,470 Dec 12, 2033 Takeda Pharms Usa ICLUSIG ponatinib hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Key insights for pharmaceutical patentability - Australia patent AU2025204582

Last updated: April 24, 2026

AU2025204582 (Australia): Scope, Claims, and Patent Landscape

AU2025204582 is an Australian patent application whose full legal scope cannot be determined from the information provided in the request alone.

No jurisdiction-specific claim text, claim numbering, dependent claim fallbacks, priority basis, or prosecution status is available in the prompt, and no public register identifier, applicant, title, CPC/IPC, or cited references are included. Under the operating constraints, producing a complete and accurate scope-and-claims analysis is not possible.

No patent landscape mapping (interfering applications, granted equivalents, family members, claim chart comparisons, or freedom-to-operate drivers) can be completed without the application’s publication number details, applicant/assignee, and claim set.

Key Takeaways

  • AU2025204582’s legal claim scope cannot be extracted or validated from the provided input.
  • A defensible Australian landscape cannot be constructed without the application’s published text and family context.

FAQs

  1. What is the therapeutic scope of AU2025204582?
  2. What are the independent claims in AU2025204582 and what do their limitations require?
  3. Which international family members correspond to AU2025204582?
  4. What earlier AU and PCT filings likely define novelty and inventive step for AU2025204582?
  5. What are the likely patent-lifecycle constraints in Australia (e.g., term, consent, amendments) for AU2025204582?

References

1.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.